THE "NEW" PROSTATE CANCER INFOLINK

The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers.

We have already reported on some of these issues, but it’s never a bad idea to hear more than one opinion! So … here’s a short summary of some of the important things you can now find on the UroToday web site:

• A report on the presentation by Fizazi et al. about the results of the LATITUDE trial (the phase III, double-blind, randomized trial of ADT with abiraterone acetate + prednisone or placebos in newly diagnosed, high-risk, mCRPC)
• A report on the presentation by Dr. Alicia Morgans dealing with “Physical and cognitive effects of systemic therapy in older men with prostate cancer”
• A report on a presentation by Dr. Johann De Bono on “Targeting DNA repair mutations” in mCRPC
• A 30-minute audio of a conversation between Dr. Alicia Morgans and Dr. Charles Ryan about the implications of the data from the LATITUDE and the STAMPEDE trials presented at ASCO
• A report by Dr. Heather Cheng on the clinical implications of new data regarding genomic sequencing in prostate cancer

Access to the UroToday web site does require you to register, but there is no cost involved and you can limit the number of e-mails that you get about new material on the UroToday web site.

We should acknowledge the hard work at ASCO of Dr. Zachary Klaassen, of the University of Toronto, Princess Margaret Cancer Centre, who seems to have written many of these reports for UroToday.

Filed under: Diagnosis, Management, Treatment | Tagged: advanced, ASCO, castration-resistant, genomic, mCRPC, metastatic, sequencing |